Leading the charge in the GLP1 market are five key drugs: Mounjaro, Ozempic, Wegovy, Cagrisema, and Rybelsus, which are forecast to capture 83% of the GLP-1 agonist market by 2029.

Using the TriNetX database, Hagedorn and colleagues categorized patients aged 65 years or older based on whether they received GLP-1 agonists (n = 37,099) or any other antidiabetic drugs (n = 37,013).

The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...

There are several drug tools to activate or antagonize 5-HT 4 receptors: RS 100235, SB 204070, and GR 113808 are selective high-affinity antagonists, while BIMU8, ML 10302, and RS 67506 represent ...

CC BY-ND Antagonist drugs An antagonist is a drug designed to directly oppose the actions of an agonist. Again, using the lock and key analogy, an antagonist is like a key that fits nicely into ...

Both agonists and antagonists of luteinizing-hormone-releasing hormone (LHRH) are in clinical use for a wide range of cancers, benign prostatic hypertrophy, fibroids and reproductive disorders ...

Review Article Published: February 2008 Drug Insight: selective agonists and antagonists of the glucocorticoid receptor Andrew McMaster & David W Ray Nature Clinical Practice Endocrinology ...